Status:
COMPLETED
Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Breast Cancer
Eligibility:
All Genders
Brief Summary
Assess and characterize the real-world cyclin-dependent kinase 4/6 inhibitor (CDKI) use in advanced/metastatic breast cancer (a/mBC), evaluate treatment persistence, and quantify CDKI dose adjustments...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Male and female patients of all ages.
- Patients with at least one CDKI consumption from November 2018 to May 2023.
- Patients with consumptions in Gynecology and Oncology specialties.
- Exclusion criteria:
- Consumption patterns of target drugs that are not compatible with any known a/mBC treatment regimen.
- Patients in early stages of breast cancer.
Exclusion
Key Trial Info
Start Date :
March 29 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
1926 Patients enrolled
Trial Details
Trial ID
NCT07223476
Start Date
March 29 2024
End Date
July 1 2024
Last Update
October 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936